Literature DB >> 10961453

Virulence factors and the pathogenesis of disease caused by Streptococcus pneumoniae.

T J Mitchell1.   

Abstract

Streptococcus pneumoniae is a major pathogen of man causing diseases such as pneumonia, meningitis and otitis media. The mechanisms by which this organism causes these diseases are still largely unknown. The use of molecular approaches to identifying and studying putative virulence factors in combination with the application of animal models has allowed some of the mechanisms of the disease process to be defined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961453     DOI: 10.1016/s0923-2508(00)00175-3

Source DB:  PubMed          Journal:  Res Microbiol        ISSN: 0923-2508            Impact factor:   3.992


  26 in total

1.  Evolution and virulence of serogroup 6 pneumococci on a global scale.

Authors:  D Ashley Robinson; David E Briles; Marilyn J Crain; Susan K Hollingshead
Journal:  J Bacteriol       Date:  2002-11       Impact factor: 3.490

2.  Decreased virulence of a pneumolysin-deficient strain of Streptococcus pneumoniae in murine meningitis.

Authors:  Andreas Wellmer; Gregor Zysk; Joachim Gerber; Tammo Kunst; Matthias Von Mering; Stefanie Bunkowski; Helmut Eiffert; Roland Nau
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

3.  The mechanism of pneumolysin-induced cochlear hair cell death in the rat.

Authors:  Maryline Beurg; Aziz Hafidi; Liam Skinner; Graeme Cowan; Yannick Hondarrague; Tim J Mitchell; Didier Dulon
Journal:  J Physiol       Date:  2005-07-28       Impact factor: 5.182

4.  Genome of the bacterium Streptococcus pneumoniae strain R6.

Authors:  J Hoskins; W E Alborn; J Arnold; L C Blaszczak; S Burgett; B S DeHoff; S T Estrem; L Fritz; D J Fu; W Fuller; C Geringer; R Gilmour; J S Glass; H Khoja; A R Kraft; R E Lagace; D J LeBlanc; L N Lee; E J Lefkowitz; J Lu; P Matsushima; S M McAhren; M McHenney; K McLeaster; C W Mundy; T I Nicas; F H Norris; M O'Gara; R B Peery; G T Robertson; P Rockey; P M Sun; M E Winkler; Y Yang; M Young-Bellido; G Zhao; C A Zook; R H Baltz; S R Jaskunas; P R Rosteck; P L Skatrud; J I Glass
Journal:  J Bacteriol       Date:  2001-10       Impact factor: 3.490

5.  Antibacterial activity of a competence-stimulating peptide in experimental sepsis caused by Streptococcus pneumoniae.

Authors:  Marco R Oggioni; Francesco Iannelli; Susanna Ricci; Damiana Chiavolini; Riccardo Parigi; Claudia Trappetti; Jean-Pierre Claverys; Gianni Pozzi
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 6.  Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.

Authors:  Tina Q Tan
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

7.  Lipocalin 2 deactivates macrophages and worsens pneumococcal pneumonia outcomes.

Authors:  Joanna M Warszawska; Riem Gawish; Omar Sharif; Stefanie Sigel; Bianca Doninger; Karin Lakovits; Ildiko Mesteri; Manfred Nairz; Louis Boon; Alexander Spiel; Valentin Fuhrmann; Birgit Strobl; Mathias Müller; Peter Schenk; Günter Weiss; Sylvia Knapp
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

8.  Global transcriptional analysis of clpP mutations of type 2 Streptococcus pneumoniae and their effects on physiology and virulence.

Authors:  Gregory T Robertson; Wai-Leung Ng; Joseph Foley; Raymond Gilmour; Malcolm E Winkler
Journal:  J Bacteriol       Date:  2002-07       Impact factor: 3.490

9.  Analysis of the in vitro transcriptional response of human pharyngeal epithelial cells to adherent Streptococcus pneumoniae: evidence for a distinct response to encapsulated strains.

Authors:  Hester J Bootsma; Michael Egmont-Petersen; Peter W M Hermans
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

10.  The core promoter of the capsule operon of Streptococcus pneumoniae is necessary for colonization and invasive disease.

Authors:  Mara G Shainheit; Matthew Mulé; Andrew Camilli
Journal:  Infect Immun       Date:  2013-11-25       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.